Arcus Biosciences, Inc. Capitalized Contract Cost, Amortization
Arcus Biosciences, Inc. (RCUS) reported Capitalized Contract Cost, Amortization of $3.00 million for the 12-month period ending 2024-12-31, per its 10-K filed 2025-02-25.
Financial Statements › Expense Statement › Operating Expenses
us-gaap:CapitalizedContractCostAmortization · last filed 2025-05-06
- Arcus Biosciences, Inc. capitalized contract cost, amortization for the quarter ending 2024-12-31 was $0.00.
- Arcus Biosciences, Inc. capitalized contract cost, amortization for the quarter ending 2024-09-30 was $1.00M.
- Arcus Biosciences, Inc. capitalized contract cost, amortization for the quarter ending 2024-06-30 was $0.00.
- Arcus Biosciences, Inc. capitalized contract cost, amortization for the quarter ending 2024-03-31 was $2.00M.
- Arcus Biosciences, Inc. capitalized contract cost, amortization for fiscal 2024 was $3.00M, a 200.00% increase from fiscal 2023.
- Arcus Biosciences, Inc. capitalized contract cost, amortization for fiscal 2023 was $1.00M, a 75.00% decline from fiscal 2022.
- Arcus Biosciences, Inc. capitalized contract cost, amortization for fiscal 2022 was $4.00M.
| Period end | Capitalized Contract Cost, Amortization 3 month | Capitalized Contract Cost, Amortization 6 month | Capitalized Contract Cost, Amortization 9 month | Capitalized Contract Cost, Amortization 12 month |
|---|---|---|---|---|
| 2024-12-31 | $0.00 derived: 10-K 12 month − 10-Q 9 month · filed 2025-02-25 | $1.00M derived: sum of 2 quarters · filed 2025-02-25 | $1.00M derived: sum of 3 quarters · filed 2025-02-25 | $3.00M 10-K · filed 2025-02-25 |
| 2024-09-30 | $1.00M derived: 10-Q 9 month − 10-Q 6 month · filed 2024-11-06 | $1.00M derived: sum of 2 quarters · filed 2024-11-06 | $3.00M 10-Q · filed 2024-11-06 | $3.00M derived: sum of 4 quarters · filed 2025-05-06 |
| 2024-06-30 | $0.00 derived: 10-Q 6 month − 10-Q 3 month · filed 2024-08-08 | $2.00M 10-Q · filed 2024-08-08 | $2.00M derived: sum of 3 quarters · filed 2025-05-06 | |
| 2024-03-31 | $2.00M 10-Q · filed 2025-05-06 | $2.00M derived: sum of 2 quarters · filed 2025-05-06 | ||
| 2023-12-31 | $0.00 derived: 10-K 12 month − 10-Q 9 month · filed 2025-02-25 | $1.00M 10-K · filed 2025-02-25 | ||
| 2023-09-30 | $1.00M 10-Q · filed 2024-11-06 | |||
| 2022-12-31 | $4.00M 10-K · filed 2025-02-25 |
Similar stocks
| Stock Name | Country | Market Cap | PE Ratio |
|---|---|---|---|
| Dyne Therapeutics, Inc. (DYN) | United States | $3.084B | -7.09 |
| Arcutis Biotherapeutics, Inc. (ARQT) | United States | $3.303B | 115.47 |
| Enliven Therapeutics, Inc. (ELVN) | United States | $3.307B | -35.07 |
| Amylyx Pharmaceuticals, Inc. (AMLX) | United States | $3.361B | -13.15 |
| IDEAYA Biosciences, Inc. (IDYA) | United States | $3.540B | -20.52 |
| Organon & Co. (OGN) | United States | $3.603B | 17.03 |
| PRECIGEN, INC. (PGEN) | United States | $2.757B | -12.94 |
| NewAmsterdam Pharma Co N.V. (NAMS) | $2.719B | -15.37 | |
| Xenon Pharmaceuticals Inc. (XENE) | $3.684B | -14.27 | |
| MBX Biosciences, Inc. (MBX) | United States | $2.664B | -25.36 |